Codiak BioSciences reports $23.04 million net profit for June

By Sarah Lizee

Olympia, Wash., July 19 – Codiak BioSciences, Inc. reported a $23.04 million net profit for June on $28.44 million of gross income/sales, according to its monthly operating report filed Tuesday with the U.S. Bankruptcy Court for the District of Delaware.

To compare, the company reported a $40.78 million net loss for May on zero gross income or sales. It listed $4.34 million in selling expenses, $5.23 million in general and administrative expenses, and $31 million in other expenses for May.

The cash balance at the end of June was $2.14 million, down from $11.99 million at the end of May.

Codiak BioSciences is a clinical-stage biopharmaceutical company based in Cambridge, Mass. The company filed bankruptcy on March 27 under Chapter 11 case number 23-10350.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.